ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections through the development of host defense enhancers which locally prime and boost the body's natural first line of defense against invading pathogens. Being virus-agnostic, ENA's approach offers a solution to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.
Leadership & Board
Current Number of Employees10
Current LinkedIn Followers1,513
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$22M
Total Amount Raised$22M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$22M
Latest Funding Amount$22M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
ENA Respiratory had 10 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
10Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
ENA Respiratory had 1,513 followers as of September 28, 2026. The number of followers increased by 14 (0.93%) week-over-week.
1,513Latest Followers Count
14(0.93%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.